Global Antiviral Drugs Market: Snapshot
The global antiviral drugs market is foreseen to receive a strong push in its growth due to swelling prevalence of viral infections. It could also be substantially contributed to as chronic infections that call for long-term treatment, including hepatitis B and HIV/AIDS, spread extensively across the globe. Market growth is prognosticated to gain strength with increasing cases of new viral infections and diseases. In order to counter the spread of viral infections, development of various therapies and drugs has been considerably focused upon as drugmakers give more significance to research and development.
Expected to post a 6.4% CAGR for the forecast tenure 2016-2024, the global antiviral drugs market could rake in an US$82.9 bn by the completion of the final forecast year.
HIV to Score Big with High Demand for New Drugs to Contain Spread of Infection
On the basis of disease indication, the world antiviral drugs market has been segregated into four segments, viz. respiratory viral infection, HIV infection, hepatitis viral infection, and other types of infection. Although antiviral drugs are consistently used in the treatment of these infections, HIV is foretold to achieve stronger growth in the market for the next few years. This could be on account of the dangerous increase in the incidence of HIV infection. Demand in the HIV infection market for antiviral drugs is projected to stay higher than that in other disease indication markets.
Innovation in the world antiviral drugs market and invention of new drugs could be attributed for improving the lifespan of HIV patients. Demand for new HIV drugs is forecasted to grow more in the near term as developing countries continue to make affordable drugs available to the public and promising reimbursement policies to impress patients.
In terms of type of product, the world antiviral drugs market has been classified into two main segments, i.e. generic and branded drugs. By distribution channel, the report has divided the market into online pharmacy, retail pharmacy store, and hospital pharmacy store.
North America to Sit Atop Growth Using Revenue Earned from Expensive Novel Drugs
Having collected a colossal percentage of share in the recent past, North America could well be a candidate for securing the lead in the international antiviral drugs market. Market growth in this region is envisaged to gain momentum with high cost of new drugs complementing high purchasing power and disposable income of patients. The region could be trailed by Europe as consumers show high preference for novel drugs and the number of patients taking antiretroviral treatments surges. Other factors that could help Europe to take the second position are continuous introduction of new drugs and better diagnostic facilities.
Asia Pacific is also predicted to offer rewarding prospects in the international antiviral drugs market because of quick spread of influenza and other infectious viral diseases and increasing penetration of drugs for Zika, Ebola, and other highly infectious viruses. Other regions such as the Middle East and Africa could tread upon the heels of Asia Pacific.
Some of the top companies functioning in the international antiviral drugs market are GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Mylan N.V., and Teva Pharmaceutical Industries Ltd.
Global Antiviral Drugs Market: Overview
In past 30 years, significant progress is seen in antiviral drugs market, mainly in case of the drugs that target the entry and escaping mechanisms of viruses, with an aim of improving the quality of patient’s life by introducing broad spectrum of combination therapy drugs. Viruses rely on host’s machinery for replication as well as metabolic activities, thus antiviral agents target these mechanisms by several inhibitor classes such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors (FIs), Entry Inhibitors - CCR5 co-receptor antagonist, Protease Inhibitors (PIs), HIV Integrase strand transfer inhibitors, among others.
Demand for new and improved targeted therapies for viral diseases continues to rise, primarily due to invention of broad spectrum antiviral drugs. Introduction of combinational drug therapies with improved pharmacokinetic and pharmacodynamics properties, and focus on emerging regions for market penetration by creating awareness along with availability of affordable drugs are major opportunities for the global antiviral drugs market.
The market overview section of the report comprises qualitative analysis of the overall antiviral drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the disease indications, product type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The prevalence HIV infection and HCV infection has also been provided, along with the FDA approvals and patent expiries of major drugs by each drug class. The pipeline analysis of major market players has been given in the market overview section.
Global Antiviral Drugs Market: Segmentation
The global antiviral drugs market has been segmented on the basis of disease indication, product type, and distribution channels. On the basis of disease indication, the global antiviral drugs market is categorized as hepatitis virus infection, HIV infection, Respiratory virus infection, and others. In terms of product type, the global antiviral drugs market is divided into branded drugs, and generic drugs. Furthermore, on the basis of distribution channels, the global antiviral drugs market has been classified as hospital pharmacy store, retail pharmacy store, and online pharmacy.
The market for these disease indication, product type, and distribution channels has been extensively analyzed on the basis of factors such as drug usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (USD million) for each of these segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024.
Geographically, the antiviral drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2014 to 2024, in terms of disease indication, product type, and distribution channels, along with the CAGR (%) for the forecast period 2016 to 2024.
Global Antiviral Drugs Market: Competitive Analysis
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global antiviral drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share.
The report concludes with the profiles of major players in the global antiviral drugs market such as AbbVie, Inc., Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Mylan N.V., GlaxoSmithKline plc. Johnson & Johnson, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.
The global antiviral drugs market is segmented as follows:
By Disease Indication
- Hepatitis Virus Infection
- HIV Infection
- Respiratory Virus Infection
By Product Type
- Branded Drugs
- Generic Drugs
By Distribution Channels
- Hospital Pharmacy Store
- Retail Pharmacy Store
- Online Pharmacy
- North America
- Asia Pacific
- Latin America
- Middle East & Africa